Skip to content

S. Reed

3 papers in the library · 192 citations · publishing 2020-2022

Papers

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Journal of Contextual Behavioral Science January 1, 2020 Jordan Sloshower, Jeffrey R. Guss, R. Krause et al. 168 citations

A group designing a psilocybin-assisted therapy protocol for major depressive disorder adopted Acceptance and Commitment Therapy (ACT) as the psychotherapeutic framework, citing strong overlap between ACT's proposed mechanisms of change and those of psilocybin therapy. The psilocybin experience may provide direct experiential contact with ACT processes that increase psychological flexibility, which can then be reinforced during ACT-informed follow-up sessions. The paper describes the rationale for selecting ACT, areas of synergism between ACT and psilocybin therapy, the treatment model's structure, and its limitations.

Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel

Neurology Psychiatry and Brain Research September 1, 2020 A. Fairchild, E. Katz, S. Reed et al. 14 citations

Most people with treatment-resistant depression and a general online sample were willing to accept substantial long-term risks, including ulcerative cystitis and cognitive impairment, to achieve meaningful improvements in depression symptoms. In a survey, 54% of patients who had used esketamine and 64% of panel respondents accepted benefit-risk tradeoffs. They valued improving depression symptoms most highly and were least concerned about avoiding transient post-dose issues like dissociation or dizziness. On average, clinical-trial participants accepted risks of ulcerative cystitis up to 5% or higher to see their depression improve from severe to moderate, while panel respondents accepted somewhat lower risks, though the difference was not statistically significant.

MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial

Journal of humanistic psychology February 10, 2022 Terence H. W. Ching, Monnica T. Williams, S. Reed et al. 10 citations

A mixed-methods case study examined whether a person of color with treatment-resistant PTSD would benefit from MDMA-assisted therapy (MDMA-AT) as much as participants in earlier, less diverse trials. The participant showed quantitative improvement in PTSD symptoms. An interpretative phenomenological analysis of therapy session transcripts revealed recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional positive and negative effects beyond symptom reduction. The authors discuss these themes and offer recommendations for addressing culturally relevant material during MDMA-AT.